HPN and adenocarcinoma: Further studies showed that hepsin/myc bigenic mice generated by crossing PB-hepsin mice with the PB-Hi-myc transgenic mouse model developed invasive adenocarcinoma at 4.5 months and higher-grade adenocarcinoma at 12–17 months of age.